Clinical Trials
23 trialsNCT04595981 2025-04-27
Chemo-embolization for Head and Neck Cancer
University of Alabama at Birmingham
Phase 2 Withdrawn
NCT05608369 2025-04-04
HPV
Case Comprehensive Cancer Center
Phase 2 Withdrawn
NCT05743270 2025-03-11
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
Replimune, Inc.
Phase 2 Withdrawn
NCT06084845 2024-07-25
Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
Eastern Cooperative Oncology Group
Phase 2 Withdrawn
NCT05359692 2023-09-15
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Incyte Corporation
Phase 2 Withdrawn
NCT04834349 2023-09-13
Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04987996 2023-06-06
GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients
Providence Health & Services
Phase 2 Withdrawn
NCT04831450 2022-08-04
Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)
University of Miami
Phase 2 Withdrawn
NCT04849377 2022-07-07
RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC
Icahn School of Medicine at Mount Sinai
Phase 2 Withdrawn
NCT04607642 2021-10-11
Trial of BMX-001 or Placebo in Head and Neck Cancer Patients
BioMimetix JV, LLC
Phase 2 Withdrawn
NCT04262388 2020-11-17
DOME
University Health Network, Toronto
Phase 2 Withdrawn
NCT04093115 2020-09-03
HNSCC
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 2 Withdrawn
NCT02624999 2020-01-22
Study Comparing AlloVaxâ„¢ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck
Mirror Biologics, Inc.
Phase 2 Withdrawn
NCT03325465 2019-04-22
Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck
University of Chicago
Phase 2 Withdrawn
NCT02649530 2016-09-30
A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn
NCT01820312 2016-08-08
A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT)
University of Arkansas
Phase 2 Withdrawn
NCT02119728 2016-04-21
Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity
Roswell Park Cancer Institute
Phase 2 Withdrawn
NCT01953952 2015-03-20
Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer
Radiation Therapy Oncology Group
Phase 2 Withdrawn
NCT00095641 2013-11-08
S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT01674374 2013-05-15
Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy
Roswell Park Cancer Institute
Phase 2 Withdrawn
NCT01427205 2013-04-05
Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00084435 2012-06-14
S0217
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT00233636 2011-01-27
Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck
AstraZeneca
Phase 2 Withdrawn